ATE427351T1 - Primaten t-lymphotrophische viren - Google Patents

Primaten t-lymphotrophische viren

Info

Publication number
ATE427351T1
ATE427351T1 AT06735500T AT06735500T ATE427351T1 AT E427351 T1 ATE427351 T1 AT E427351T1 AT 06735500 T AT06735500 T AT 06735500T AT 06735500 T AT06735500 T AT 06735500T AT E427351 T1 ATE427351 T1 AT E427351T1
Authority
AT
Austria
Prior art keywords
htlv
primate
htlvs
novel
variety
Prior art date
Application number
AT06735500T
Other languages
English (en)
Inventor
Donald Burke
William Switzer
Walid Heneine
Thomas Folks
Nathan Wolfe
Mpoudi Eitel
Original Assignee
Us Gov Health & Human Serv
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Univ Johns Hopkins filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE427351T1 publication Critical patent/ATE427351T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06735500T 2005-02-21 2006-02-21 Primaten t-lymphotrophische viren ATE427351T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65448405P 2005-02-21 2005-02-21

Publications (1)

Publication Number Publication Date
ATE427351T1 true ATE427351T1 (de) 2009-04-15

Family

ID=36655074

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06735500T ATE427351T1 (de) 2005-02-21 2006-02-21 Primaten t-lymphotrophische viren
AT09075152T ATE539153T1 (de) 2005-02-21 2006-02-21 Primaten t-lymphotrophische viren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT09075152T ATE539153T1 (de) 2005-02-21 2006-02-21 Primaten t-lymphotrophische viren

Country Status (7)

Country Link
US (3) US7794998B2 (de)
EP (2) EP1880006B1 (de)
AT (2) ATE427351T1 (de)
AU (1) AU2006216838B8 (de)
CA (1) CA2598547C (de)
DE (1) DE602006006047D1 (de)
WO (1) WO2006091511A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1880006B1 (de) 2005-02-21 2009-04-01 The Government of the United States of America, as represented by The Secretary, Department of Health and Human Services Primaten t-lymphotrophische viren
WO2006133795A2 (en) * 2005-05-02 2006-12-21 Institut Pasteur A new human t-cell lymphotropic virus (htlv-3): nucleic acid and peptidic sequences thereof and method for detecting htlv-3
ATE531809T1 (de) * 2007-05-21 2011-11-15 Gov Of The Usa As Represented By The Secretary Of The Dept Of Health & Human Services Neues simianes t-zell-lymphotropes virus
US10928398B2 (en) * 2008-12-17 2021-02-23 Cornell University Method for double staining colocalized nuclear-markers in histological lymphoid or bone marrow tissue sample
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
WO2014081882A2 (en) * 2012-11-20 2014-05-30 The Trustees Of Columbia University In The City Of New York Systems and methods for analyzing coding sequences based on genetic distances

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406841B1 (en) 1993-07-01 2002-06-18 Abbott Laboratories Methods for the detection of HTLV-II antibodies employing novel HTLV-II NRA envelope peptides
EP1880006B1 (de) * 2005-02-21 2009-04-01 The Government of the United States of America, as represented by The Secretary, Department of Health and Human Services Primaten t-lymphotrophische viren

Also Published As

Publication number Publication date
EP1880006B1 (de) 2009-04-01
CA2598547C (en) 2016-01-19
AU2006216838B2 (en) 2011-04-21
CA2598547A1 (en) 2006-08-31
US20140080121A1 (en) 2014-03-20
DE602006006047D1 (en) 2009-05-14
US8541221B2 (en) 2013-09-24
ATE539153T1 (de) 2012-01-15
US7794998B2 (en) 2010-09-14
AU2006216838B8 (en) 2011-05-12
WO2006091511A8 (en) 2007-11-22
WO2006091511A2 (en) 2006-08-31
EP2194127A1 (de) 2010-06-09
WO2006091511A3 (en) 2006-12-28
AU2006216838A1 (en) 2006-08-31
EP1880006A2 (de) 2008-01-23
US20100317034A1 (en) 2010-12-16
US20080292657A1 (en) 2008-11-27
US9435000B2 (en) 2016-09-06
EP2194127B1 (de) 2011-12-28

Similar Documents

Publication Publication Date Title
ATE539153T1 (de) Primaten t-lymphotrophische viren
Peterhans et al. Pestiviruses: how to outmaneuver your hosts
WO2021226436A8 (en) Optimized nucleotide sequences encoding sars-cov-2 antigens
WO2019193183A3 (en) Novel yellow fever nucleic acid molecules for vaccination
DK1942108T3 (da) Forbindelse indeholdende basisk gruppe samt anvendelse deraf
WO2021262826A3 (en) 1'-cyano nucleoside analogs and uses thereof
EA201070794A1 (ru) Рекомбинантные антигены rsv
BRPI0519135A2 (pt) macrolÍdeos
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
BRPI0410029A (pt) dihidroquinazolinas substituìdas
WO2016178876A3 (en) Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
WO2005084315A3 (en) Pyranoindole derivatives and the use thereof for the treatment of hepatitis c virus infection or disease
EA201500643A1 (ru) Парвовирус свиней 5а, способы применения и вакцина
WO2022010938A3 (en) Catalysis deactivated angiotensin-converting enzyme 2 (ace2) variants and their uses
WO2009005040A1 (ja) 緑膿菌の外膜タンパク質pa4710
WO2007036735A3 (en) Immunogenic agents againts burkholderia psudomallei and/or burkholderia mallei, comprising lipopolysaccharide, capsular polysaccharide and/or proteins from burkholderia psuedomallei
WO2005051318A3 (en) Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
BR0314640A (pt) Inibidor de vìrus de hepatite c compreendendo, como um ingrediente ativo, alfa-glicosilceramida
MX2022003218A (es) Vacunas para abejas y metodos de uso.
Mustafa et al. Pandemic SARS Coronavirus-2 infections in humans-COVID-19
ATE515270T1 (de) Phep, eine aminosäurepermease von staphylococcus aureus
Kandi Coronavirus Disease (COVID-19)/SARS-CoV-2: hopefully, the human-virus battle ends soon on a positive note
Kalugina et al. Studying of efficiency" Duo Ekvalan" at helminthoses of horses
Ahmad et al. Nipah encephalitis-an update
ASLAN et al. The evaluation of oxidative stress in lambs with Pestivirus infection

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties